Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tocilizumab + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
A combination therapy consisting of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, and interferon alfa-2b, an antiviral and immunomodulatory agent. Tocilizumab is a recombinant humanized monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors, preventing IL-6 mediated inflammation. Interferon alfa-2b works through the JAK-STAT signaling pathway to induce antiviral effects and modulate immune responses. This combination has been studied in clinical trials for various conditions, including recurrent epithelial ovarian cancer.
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on tocilizumab + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tocilizumab + interferon alfa-2b.